1417 / 1835
Aims
1. Evaluate the
complete remission rate
of pembrolizumab
combined with ISRT as an alternative to HDT/ASCT in early stage
rel/ref HL patients
2. Determine the
single agent response rate
of pembrolizumab in
this population
3. Determine the
toxicity and 2-year EFS
with this strategy
4. Evaluate
biological markers of response and resistance:
1. Tumor andTME immune evasion markers
2. Development of anti-tumor T-cell clonal expansion
3. T-effector:T-reg ratio
4. SerumTARC